Is LQDA stock a Buy, Sell, or Hold?

Based on our analysis, LQDA is currently a HOLD with moderate confidence. 📊 HOLD: LQDA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

What is the fair value of LQDA stock?

Our analysis estimates the fair value range for LQDA to be between $32.63 and $37.32. The current price is $35.41.

What is the analyst price target for LQDA?

The average Wall Street analyst price target for LQDA is $50.67. This implies a potential upside of 44.6% from current levels.

LQDA Stock Analysis: Buy, Sell, or Hold?

LQDA - Liquidia Corporation Common Stock

PHARMACEUTICAL PREPARATIONS

$35.41

0.38 (1.08%) ▲

5d: -0.25%

30d: +14.15%

90d: +2.91%

HOLD

MODERATE Confidence

Protect Your LQDA Gains

Analysis Updated: Mar 30, 2026 12:00 AM ET

Earnings: May 14, 2026

Smart Money Accumulation

LQDA is down 3.8% this week, but smart money is accumulating calls. Top strike: $37.5 2026-05-15 with 1,102 OI. Call ratio: 71% View Scanner →

Strength: 4.0/10

Get Alerted When LQDA Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: LQDA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$133.62

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$82.97

57.3% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.1x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: LQDA is currently trading at $35.41, which is considered fair relative to its 30-day fair value range of $32.63 to $37.32. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.7) compared to its historical average (13.1). Remarkably, the market is currently pricing in an annual earnings decline of 20.1% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, LQDA is in a uptrend. Immediate support is located at $34.21, while resistance sits at $38.25.

Market Sentiment: LQDA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $50.67 (+44.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position FAIR

Fair Price Range $32.63 - $37.32

Company Quality Score 58/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 59.6%

Protect Your Profits

Holding LQDA? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

NEUTRAL: Price in fair range
BULLISH: Options cheap (IV 0th percentile)
BEARISH: Weak technical setup (25/100)
BULLISH: High volume confirmation
BULLISH: Trading 44.6% below Wall St target ($50.67)

Fair Price Analysis

30-Day Fair Range $32.63 - $37.32

Current vs Fair Value FAIR

Expected Move (7 Days) ±$7.46 (21.1%)

Support & Resistance Levels

Support Level $34.21

Resistance Level $38.25

Current Trend Uptrend

Technical data as of Mar 30, 2026

Fundamental Context

Forward P/E (Next Year Est.) 6.69

Wall Street Target $50.67 (+44.6%)

Revenue Growth (YoY) 3054.6%

Profit Margin -43.5%

Valuation Discount vs History -20.1% cheaper

PE vs Historical 6.7 vs 13.1 CHEAP

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -20.1% (market-implied from PE analysis)

1-Year Target $31.53 (-10%)

2-Year Target $28.37 (-19%)

3-Year Target $25.54 (-27%)

3-Yr Target (if PE normalizes) (PE: 7→13) $50.02 (+43%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 22.4, Growth: 103.2%) $395.99 (+1030%)

Base: (SPY PE: 6.7, Growth: 103.2%) $118.23 (+238%)

Bear: (PE: 5.7, Growth: 103.2%) $100.49 (+187%)

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 6.7 to 13.1

Stabilization Target: $68.62 (+95.9%)

PE Expansion Potential: +95.9%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: March 30, 2026 1:57 PM ET
Data refreshes hourly during market hours. Next update: 2:57 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is LQDA showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Dana Boyle SELL 1580 shares 2026-01-26

Jason Adair SELL 688 shares 2026-01-26

Dana Boyle SELL 11047 shares 2026-01-12

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for LQDA.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
NBIX Neurocrine Biosciences I…	STRONG BUY 25 analysts	$178	63 BUY
ZTS Zoetis Inc	STRONG BUY 19 analysts	$151	55 HOLD
LNTH Lantheus Holdings Inc	STRONG BUY 13 analysts	$91	55 HOLD
HCM HUTCHMED DRC	STRONG BUY 14 analysts	$21	63 BUY
BCRX BioCryst Pharmaceuticals…	STRONG BUY 12 analysts	$21	56 HOLD

NBIX Neurocrine Biosci…

63 BUY

ZTS Zoetis Inc

55 HOLD

LNTH Lantheus Holdings…

55 HOLD

HCM HUTCHMED DRC

63 BUY

BCRX BioCryst Pharmace…

56 HOLD

Advanced LQDA Option Strategies

Professional options setups generated by AI based on today's LQDA price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for LQDA

LQDA Technical Chart LQDA Price Prediction LQDA Earnings Date LQDA Investment Advisor LQDA Fair Price Analyzer LQDA Options Advisor LQDA Options Chain LQDA Options Analysis LQDA Competitors

Compare LQDA with Other Stocks

Create New Comparison

Tradestie